

Palak J Trivedi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4315588/publications.pdf>

Version: 2024-02-01

57
papers

3,520
citations

147801

31
h-index

155660

55
g-index

60
all docs

60
docs citations

60
times ranked

3428
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1687-1700.e4.	4.4	31
2	Emerging drugs for the treatment of primary sclerosing cholangitis. <i>Current Opinion in Pharmacology</i> , 2022, 62, 23-35.	3.5	5
3	Mucosal immunity in primary sclerosing cholangitis: from the bowel to bile ducts and back again. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 104-113.	2.3	5
4	Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. <i>American Journal of Human Genetics</i> , 2022, 109, 928-943.	6.2	22
5	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1248-1257.	4.4	25
6	Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholestatic Liver Disease (EXCITED) feasibility trial. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000579.	2.7	6
7	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 156-158.	8.1	49
8	Recent advances in clinical practice: epidemiology of autoimmune liver diseases. <i>Gut</i> , 2021, 70, 1989-2003.	12.1	91
9	Editorial: liver disease in secondary care “money or your life”™. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 854-855.	3.7	1
10	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	4.4	57
11	Novel Use of Normothermic Machine Perfusion of the Liver: A Strategy to Mitigate Unexpected Clinical Events. <i>Transplantation</i> , 2020, 104, e281-e282.	1.0	4
12	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
13	Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. <i>Gastroenterology</i> , 2020, 159, 915-928.	1.3	94
14	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	2
15	PS-016-Prospective evaluation of serum alkaline phosphatase variability and prognostic utility in primary sclerosing cholangitis using controlled clinical trial data. <i>Journal of Hepatology</i> , 2019, 70, e12-e13.	3.7	2
16	Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2785-2792.e3.	4.4	43
17	Challenges in the use of corticosteroids in the management of autoimmune hepatitis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2019, 80, 594-599.	0.5	4
18	FRI-062-Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patients’™ perspective. <i>Journal of Hepatology</i> , 2019, 70, e412-e413.	3.7	6

#	ARTICLE	IF	CITATIONS
19	Risk stratification in primary sclerosing cholangitis: It's time to move on from replicating imperfection and break the glass ceiling. <i>Journal of Hepatology</i> , 2019, 71, 867-870.	3.7	9
20	FRI-061-Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 70, e412.	3.7	1
21	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	4.4	54
22	Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 636-643.	3.7	64
23	Challenges in the use of corticosteroids in the management of autoimmune hepatitis. <i>Gastrointestinal Nursing</i> , 2019, 17, S30-S36.	0.1	0
24	Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. <i>Hepatology</i> , 2019, 69, 2120-2135.	7.3	58
25	Grand round: Autoimmune hepatitis. <i>Journal of Hepatology</i> , 2019, 70, 773-784.	3.7	33
26	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , 2019, 156, 96-107.e1.	1.3	82
27	The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video). <i>Gastrointestinal Endoscopy</i> , 2018, 88, 95-106.e2.	1.0	27
28	Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. <i>Gut</i> , 2018, 67, 1135-1145.	12.1	52
29	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	7.3	55
30	Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths. <i>American Journal of Gastroenterology</i> , 2018, 113, 1437-1439.	0.4	4
31	Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S641-S652.	1.3	105
32	The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 322-332.	3.7	30
33	Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 71-83.	2.4	10
34	The gut-adherent microbiota of PSC+IBD is distinct to that of IBD. <i>Gut</i> , 2017, 66, 386.1-388.	12.1	132
35	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
36	Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	3.7	202

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 957-965.	3.7	31
38	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <i>Hepatology</i> , 2017, 65, 907-919.	7.3	79
39	Letter: the therapeutic potential of targeting <scp>CCL</scp>25/<scp>CCR</scp>9 in colonic inflammatory bowel disease â€“ reading between the lines. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 307-308.	3.7	2
40	Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. <i>Journal of Autoimmunity</i> , 2016, 68, 98-104.	6.5	70
41	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	12.1	139
42	Obeticholic acid for the treatment of primary biliary cirrhosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 13-26.	3.1	51
43	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. <i>Hepatology</i> , 2016, 63, 644-659.	7.3	57
44	Gutâ€™liver immunity. <i>Journal of Hepatology</i> , 2016, 64, 1187-1189.	3.7	93
45	The Immunogenetics of Autoimmune Cholestasis. <i>Clinics in Liver Disease</i> , 2016, 20, 15-31.	2.1	22
46	Renaming primary biliary cirrhosisâ€™clarity or confusion?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 678-679.	17.8	11
47	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	1.3	330
48	Reply to: â€œAST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosisâ€•. <i>Journal of Hepatology</i> , 2014, 61, 1445-1446.	3.7	12
49	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	1.3	365
50	Good Maternal and Fetal Outcomes for Pregnant Women WithÂPrimary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1179-1185.e1.	4.4	56
51	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. <i>Journal of Hepatology</i> , 2014, 60, 1249-1258.	3.7	113
52	Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments. <i>Hepatology International</i> , 2013, 7, 28-47.	4.2	15
53	Mucosal immunity in liver autoimmunity: A comprehensive review. <i>Journal of Autoimmunity</i> , 2013, 46, 97-111.	6.5	110
54	Treatment of autoimmune liver disease: current and future therapeutic options. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 119-141.	2.5	40

#	ARTICLE	IF	CITATIONS
55	PSC, AIH and overlap syndrome in inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 420-436.	1.5	47
56	Review article: overlap syndromes and autoimmune liver disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 517-533.	3.7	109
57	M2049 Fracture Risk Assessment Using DXA and FRAX in Patients with Celiac Disease. Gastroenterology, 2009, 136, A-474.	1.3	0